Jobs
-
French device company Biocorp announced that it has signed an agreement with Lindal Group subsidiary VARI under which VARI will incorporate Biocorp’s Inspair inhaler sensor into its devices in a deal that includes exclusivity for… Read more . . .
-
According to Iconovo, Japanese pharmaceutical company TOA Pharmaceuticals has placed a “significant” order for DPIs to be used in a feasibility study. Iconovo will produce two customized versions of the inhaler and will conduct the… Read more . . .
-
Circassia Pharmaceuticals notified AstraZeneca that it will exercise its option to acquire the full US commercial rights to the Tudorza aclidinium DPI, the company said. Circassia acquired US rights to Tudorza and to Duaklir aclidinium/formoterol… Read more . . .
-
Acerus Pharmaceuticals said that a Phase 1 trial of its intranasal formulation of tetrahydrocannabinol-rich cannabis oil in 12 healthy volunteers demonstrated that the bioavailability of TCH from the nasal formulation was 2.2 times better than… Read more . . .
-
Avanir and Optinose have separately announced the termination of the license agreement that gave Avanir the North American rights to develop and commercialize Onzetra Xsail intranasal sumatriptan. The license agreement, which was initially announced in… Read more . . .
-
Zambon has announced that its colistimethate sodium powder for nebulized delivery as a solution by the Philips i-neb nebulizer system, has received QIDP and fast track designations from the FDA for the prevention of exacerbations… Read more . . .
-
Copley Scientific has announced the launch of a 316 stainless steel mixing inlet for use in aerodynamic particle size distribution (APSD) measurement, available in versions for both ACI and NGI impactors. The company also announced… Read more . . .
-
According to Auris Medical, the FDA has granted orphan drug designation to its intranasal betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS). The company also said that it has signed a letter… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has raised $67.5 million in a Series D financing round led by KKR and Norwest Venture Partners, the company said. Existing investors Vivo Capital, 5AM Ventures and venBio Partners also… Read more . . .
-
Vast Therapeutics (formerly Novoclem) has announced that Shionogi & Co. was the sole investor in a Series A financing round that will fund pre-clinical and Phase 1 development of the company’s dry powder nitric oxide… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany